Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Greggs

(Sharecast News) - Analysts at Berenberg raised their target price on bakery chain Greggs from 3,550.0p to 3,990.0p on Friday as it noted that customer appeal had broadened as its market share was expanding. Berenberg noted that Greggs has made "encouraging progress" across multiple growth initiatives, which were now showing signs of success as the company's market share grows to an all-time high and benefits from a broader customer appeal.

The German bank, which reiterated its 'buy' rating on the stock, stated that Greggs has shown "resilient top-line growth" as it increasingly benefits from the introduction of evening sales and the expansion of its store estate, as well as delivery and loyalty/app improvements.

"We update our earnings forecasts to reflect slightly higher rates of revenue growth, which are more than offset by an increase in cost growth estimates. These changes reflect the company's FY 2023 results (reported on 5 March), and drive a respective 4% and 5% decline in our FY 2024E and FY 2025E adjusted-PBT forecasts versus our prior expectations," said Berenberg.

"We model LFL revenue growth of 8.5% yoy in H1 2024E and assume pricing equal to cost guidance (c4-5% yoy), before a slight reversion of revenue growth in H2 as pricing moderates. We increase our cost growth estimates to model flat profit before tax margins across FY 2024E to FY 2025E given the emergence of heightened labour costs, coupled with investment relating to newly introduced sites."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Honda guides to profit decline this year as sales stall
(Sharecast News) - Japanese carmaker Honda said that annual profits are expected to fall after a huge jump in the year just gone, with currency movements and rising costs estimated to weigh on the bottom line.
Polarean shares jump on MRI system order
(Sharecast News) - Advanced MRI technology specialist Polarean Imaging shares were surging on Friday, after receiving its second de novo order for a new Xenon MRI System from the University of Alabama at Birmingham (UAB) Hospital.
Ascent upbeat on progress as Lisbon Valley gas and helium investment
(Sharecast News) - Ascent Resources updated the market on operations in its investment into GNG Partners, the owner of the 60 million standard cubic feet Lisbon Valley gas and helium processing plant in Utah, on Friday.
Celadon Pharmaceuticals raises £2.1m for working capital
(Sharecast News) - Medical cannabis specialist Celadon Pharmaceuticals announced on Friday that it has raised £2.1m to provide it with additional working capital.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.